

APPLICANTS: Wands et al.

FILED: Herewith

## REMARKS

Claims 23-25, and 39-53 are pending, claims 1-22 and 26-38 having been canceled as being drawn to a non-elected invention. New claims 39-53 have been added. New claims 39-43 are supported by disclosure on page 8, lines 5-21, of the specification. New claims 44-45 are supported by disclosure on page 1, lines 25-31, of the specification. New claims 46-47 are supported by disclosure on page 22, lines 5-6, of the specification. New claim 48 is supported by disclosure on page 52, lines 11-14, of the specification. New claims 49-51 are supported by disclosure on page 48, line 28, to page 49, line 17, of the specification. New claims 52-53 are supported by disclosure on page 17, line 29, and on page 41, lines 30-33, of the specification.

No new matter has been added by this amendment.

## CONCLUSION

Applicants believe that the claims are in condition for allowance. The Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 21486-032.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306

Attorney for Applicants

c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542 6000

Fax: (617) 542-2241

APPLICANTS: Wands et al.

FILED: Herewith

Appendix

In the specification:

On page 1, line 2, after the title, insert:

--This application is a divisional of patent application U.S. Serial Number 09/436,184, filed on November 8, 1999, the entire contents of which is hereby incorporated by reference.--

In the claims:

Cancel claims 1-22 and 26-38.

Add claims 39-53.

--39. The method of claim 23, wherein said compound is a vitamin D analogue.--

--40. The method of claim 23, wherein said compound is EB1089.--

--41. The method of claim 23, wherein said compound is Wortmannin.--

--42. The method of claim 23, wherein said compound blocks and IRS phosphorylation site of SEQ ID NO:5.--

--43. The method of claim 23, wherein said compound binds to residues 46, 465, 551, 612, 632, 662, 732, 941, 989, or 1012 of SEQ ID NO:5.--

--44. The method of claim 23, wherein said tumor is selected from the group consisting of colon cancer, breast cancer, pancreatic cancer, liver cancer, and cancer of the bile ducts.--

--45. The method of claim 23, wherein said tumor is a cancer of the central nervous system.--

APPLICANTS: Wands et al.

FILED: Herewith

- 46. The method of claim 23, wherein said tumor is a hepatocellular carcinoma.--
- 47. The method of claim 23, wherein said tumor is a cholangiocarcinoma.--
- 48. The method of claim 23, wherein said compound is an antibody or fragment thereof.--
- 49. The method of claim 23, wherein said compound is a dominant negative IRS mutant.--
- 50. The method of claim 49, wherein said mutant comprises a mutation at position 897 of SEQ ID NO:5.--
- 51. The method of claim 49, wherein said mutant comprises a mutation at position 1180 of SEQ ID NO:5.--
- 52. The method of claim 23, wherein said tumor is a glioblastoma.--
- 53. The method of claim 23, wherein said tumor is a neuroblastoma--

TRA 1540149v1